Medical cannabis production facilities are characterized by their close cooperation with experts. This is also evidenced by the company Geschur Medical, whose cultivation facility is located in Horka nad Moravou. We interviewed CEO Adam Nastoupil (AN) and Tibor Béres (TB) from Palacký University, whose specialization is phytochemical analysis of natural substances.
When and why did you decide to start growing cannabis for medicinal use?
TB: The offer to grow medicinal cannabis came during the Covid crisis. Scientists from Palacký University are regularly encouraged to engage in contractual research in addition to primary research. I have always enjoyed that, so I gladly accepted the offer.
How long did it take from the initial idea to the first harvest?
AN: It was definitely not a leap-forward process, but a gradual journey that took several years. From the initial idea, we had to go through both the technological design of the operation and, above all, regulatory preparation, which is essential for medicinal cannabis.
We are currently working on a project related to the valorization of waste from the grow room.
In parallel, we were building a facility that met pharmaceutical standards and setting up processes to be sustainable in the long term. For us, the first harvest was not a beginning, but rather a confirmation that the entire system was working as we intended.
Why Olomouc and how did you get together with scientists from Palacký University?
TB: Olomouc has historically significant moments in modern cannabis treatment. Professors Hanuš, Kabelík, Krejčí and Šantavý were responsible for this.
AN: The collaboration with Palacký University came about naturally – we knew from the beginning that we didn’t want to go down the path of purely commercial production without a deeper understanding of the plant. On the contrary, we wanted to build the project on data, research, and the ability to systematically evaluate things.
TB: Smaller companies often do not have their own research department and there is a demand for research. Contract research is attractive for the university. So I think the cooperation is based on mutual need. We are currently working together on a project related to the valorization of waste from the grow room.
What makes you different from other similar medical cannabis producers?
TB: We strive to produce medicinal cannabis sustainably. Local resources are the key to quality. Among other things, we use high-quality water from the Litovelské Pomoraví Protected Landscape Area for cultivation, and the plants are strong and healthy thanks to the high number of sunny days here in Haná. The powerful LED lighting is powered by solar panels.

AN: Our ambition from the beginning was not to be the largest, but to be a consistent and trustworthy producer in the long term. I see the difference mainly in the approach to the entire process. We try to build production in such a way that it is maximally standardized and reproducible over time, not dependent on one successful harvest.
What are your expectations and ideas regarding the resulting cultivars?
AN: Stability and predictability are our primary requirements. In addition to cannabinoid content, we also monitor the overall quality of the flower, structure, terpene content and processing behavior.
How long does it take to stabilize a cultivar and what are the pitfalls?
AN: In my opinion, it is important to distinguish between breeding a new cultivar and stabilizing its production. In commercial operations, we primarily work with already stabilized genotypes and focus on ensuring that their properties are consistent within each harvest. The catch is that even small variations in the environment can affect the resulting profile, so the most important work lies in precisely controlling the conditions.
TB: Stabilizing traits can lead to a reduction in potency, so it is not always desirable. The current demand in the medical cannabis field is for genotypes with very high cannabinoid content, so the heterosis effect is used, where the offspring resulting from the crossing of different parents show better traits than both parents, and subsequent vegetative propagation.
What does your offering currently look like in terms of THC and CBD percentages?
TB: We can currently offer genotypes with THC and CBD dominance and also a balanced ratio of them.
AN: We try to remain flexible so that we can respond to the specific demands of the market and individual partners.
Are you going to launch a variety that is completely unique in some way?
AN: Rather than one-off “exceptionalism”, we focus on long-term quality and practical applicability. Of course, we tackle interesting projects and are already working with genetics that go beyond the usual standard.
Our ambition is not to be the largest, but to be a consistent and trustworthy producer in the long term.
TB: Our exclusive genotype is a cultivar with a balanced ratio of CBD and THC with a specific terpene profile, bred by experts from the St. Anne's University Hospital in Brno.
Can you tell me how much you had to invest?
AN: Entering this industry is capital and time-consuming. It's not just about the cultivation technology itself, but also about meeting regulatory requirements, setting up processes and ensuring quality. I would leave specific numbers aside, but in general, if the project is to operate in the long term and in accordance with the required standards, it is an investment of tens of millions of crowns.
Are you planning to export dry goods to Germany, for example? How do the requirements of the market there differ?
TB: The German market is unique in that it rejects cannabis that has been irradiated with gamma radiation. We prioritize the safety of cannabis use, so we have it sterilized.
AN: It is crucial for us to be able to guarantee quality in the long term and meet all the partner's requirements before entering a new market. At the moment, we are mainly focused on stabilizing and developing the domestic and regional environment. We see export as a natural next step, but we do not want to rush it.
















